Private company
Aptinyx Inc.
American pharmaceutical preparations company, incorporated in Delaware1
In its 2023 annual report the company says: “We are a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel, proprietary, synthetic small molecules for the treatment of brain and nervous system disorders. We focus our efforts on targeting and modulating N-methyl-D-aspartate receptors, or NMDArs, which are vital to normal and effective function of the brain and nervous system.”51 It is headquartered in Evanston, Illinois.1
Last updated Oct 21, 2026.
Overview
Financials
From the company’s reports to the SEC. Every number links to the filing it came from.
Key numbers, fiscal 2021
Where the money goes
Where each dollar of revenue went, fiscal 2021
- Research and development100¢$55.4M
Out of $1.0M in revenue.34 The company lost money this year.
Financial statements
| Fiscal year | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 |
|---|---|---|---|---|---|---|
| Revenue | $5.0M5 | $6.6M6 | $3.7M7 | $1.6M4 | $1.0M3 | |
| Research and development | $31.6M5 | $48.8M6 | $44.3M7 | $32.8M4 | $55.4M3 | |
| Operating expenses | $75.5M3 | |||||
| Operating income | -$32.2M5 | -$54.9M6 | -$59.6M7 | -$50.8M4 | -$74.5M3 | |
| Income tax | $05 | $06 | $07 | $04 | ||
| Net income | -$32.1M5 | -$53.3M6 | -$57.4M7 | -$50.1M4 | -$74.9M3 | |
| Earnings per share | -$1.024 | -$1.113 | ||||
| Earnings per share (diluted) | -$1.024 | -$1.113 | ||||
| Shares (weighted, basic) | 67.2M shares3 | |||||
| Shares (weighted, diluted) | 67.2M shares3 |
| Fiscal year | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 |
|---|---|---|---|---|---|---|
| Cash | $17.0M5 | $92.1M5 | $150.6M6 | $98.8M7 | $141.0M4 | $106.1M3 |
| Current assets | $95.0M5 | $153.3M6 | $105.1M7 | $149.6M4 | $114.7M3 | |
| Property, plant and equipment | $185.0K3 | |||||
| Total assets | $97.3M5 | $155.6M6 | $106.5M7 | $150.6M4 | $114.9M3 | |
| Accounts payable | $622.0K3 | |||||
| Short-term debt | ||||||
| Current liabilities | $4.4M5 | $5.9M6 | $4.9M7 | $4.6M4 | $5.7M3 | |
| Long-term debt | $14.2M3 | |||||
| Total liabilities | $4.7M5 | $6.3M6 | $5.2M7 | $4.7M4 | $20.2M3 | |
| Retained earnings | -$287.9M3 | |||||
| Shareholders’ equity | -$8.6M5 | -$39.7M6 | $149.3M7 | $101.3M4 | $145.9M3 | $94.8M3 |
| Shares outstanding | 5.3M shares5 | 33.3M shares6 | 33.7M shares7 | 63.3M shares4 | 67.7M shares3 |
Cash flow is reported year to date, not quarter by quarter, so there are no separate quarterly figures.
| Fiscal year | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 |
|---|---|---|---|---|---|---|
| Cash from operations | -$32.7M5 | -$47.4M6 | -$52.1M7 | -$42.4M4 | -$63.4M3 | |
| Depreciation and amortization | $526.0K3 | |||||
| Stock-based compensation | $9.7M3 | |||||
| Capital spending | $1.6M5 | $407.0K6 | $43.0K7 | $214.0K4 | ||
| Free cash flow | -$34.3M | -$47.9M | -$52.1M | -$42.6M | ||
| Cash from investing | $121.0K3 | |||||
| Cash from financing | $28.3M3 |
Corporate structure
Aptinyx Inc. sits at the top of its group. 1 entity, 1 country on record. Switch between the flow chart and the network, and select any entity to see its details.
Major holders of Aptinyx Inc.
- Artal International S.C.A. Filed SC 13G/A on Aptinyx Inc., latest Feb 9, 2024 (2 filings since Feb 13, 2023)
- ADAMS STREET PARTNERS LLC Filed SC 13D/A on Aptinyx Inc., latest Jun 27, 2023
- Longitude Capital Partners II, LLC Filed SC 13D/A on Aptinyx Inc., latest Mar 16, 2023 (2 filings since Feb 14, 2023)
- John A. Kryzanowski Filed SC 13G/A on Aptinyx Inc., latest Jan 20, 2023 (5 filings since Jun 24, 2022)
- New Leaf Ventures III, L.P. Filed SC 13D/A on Aptinyx Inc., latest Feb 11, 2022
- Aptinyx Inc. Evanston, Illinois
Built from major holders from Schedules 13D and 13G. Each entity in the chart links to its source.
What it owns
What Aptinyx Inc. reports owning in its annual reports to the SEC: buildings, land and equipment, real estate and locations, investments, intangible assets and inventory, at the end of its latest fiscal year and a year before.
Property and equipment
| Item | Latest | A year before | Change |
|---|---|---|---|
| Accumulated depreciation | $1.5M3 Dec 31, 2022 | $1.3M3 Dec 31, 2021 | +11.4% |
| Property and equipment, net | $32.0K3 Dec 31, 2022 | $185.0K3 Dec 31, 2021 | −82.7% |
| Operating-lease assets (leased space) | $305.0K3 Dec 31, 2022 |
Real estate and locations
| Item | Latest | A year before | Change |
|---|---|---|---|
| Area of real estate | 22,672 sq ft3 Apr 6, 2022 | 6,172 sq ft3 Jul 18, 2018 | +267.3% |
Investments
Leadership
Who has led Aptinyx Inc., and when. Pick a name to see everywhere that person has worked.
Chief executive
President
Chief financial officer
- Chief executive officerNorbert G. Riedel Jun 20, 2018 to Dec 8, 202111
- ChairNorbert G. Riedel Jan 5, 2023 to Jan 5, 202312
- PresidentNorbert G. Riedel Jun 20, 2018 to Feb 28, 202011
- Chief financial officerAshish Khanna Jun 20, 2018 to Jan 5, 202313
Board members and other officers (15)
- Chief Development OfficerDavid Houck Jun 20, 2018 to Jan 7, 201914
- Chief Scientific OfficerJoseph R. Moskal Jun 20, 2018 to May 17, 201915
- Chief Medical OfficerTorsten M. Madsen Jun 20, 2018 to Jan 30, 201916
- Board memberJoan W. Miller May 12, 2021 to May 31, 202217
- Board memberGilmore Neil O'Neill Oct 22, 2021 to May 31, 202218
- Board memberHenry O. Gosebruch May 7, 2019 to May 31, 202219
- Board memberRachel E. Sherman Sep 4, 2019 to May 31, 202220
- Board memberAdam Koppel Jun 20, 2018 to May 31, 202221
- Board memberJames N. Topper Jun 20, 2018 to Apr 2, 202022
- Board memberLiam Ratcliffe Jun 20, 2018 to Apr 2, 201923
- Board memberNorbert G. Riedel Jun 20, 2018 to Dec 8, 202111
- Board memberPatrick G. Enright Jun 20, 2018 to May 31, 202224
- Board memberRobert J. Hombach Jun 20, 2018 to May 31, 202225
- Board memberTerry P. Gould Jun 20, 2018 to May 31, 202226
- Board memberWilbur H. Gantz Jun 20, 2018 to Apr 2, 202027
Timeline
- Dec 21, 20238-K Other events28
- Dec 18, 20238-K Other events29
- Jul 3, 20238-K Executive or director change; Shareholder vote30
- May 11, 20238-K Listing notice or transfer31
- May 5, 20238-K Executive or director change; Other events32
- Apr 25, 20238-K Ended a material agreement33
- Apr 18, 20238-K Executive or director change34
- Mar 30, 20238-K Results of operations35
- Mar 1, 20238-K Exit or restructuring costs36
- Feb 27, 20238-K Other events37
- Dec 8, 20228-K Listing notice or transfer38
- Dec 1, 20228-K Executive or director change39
- Jun 20, 2018New chief executive Norbert G. Riedel becomes CEO11
Calendar
When it reported results
- Mar 30, 2023Reported quarterly or annual results35
- Nov 8, 2022Reported quarterly or annual results40
- Aug 4, 2022Reported quarterly or annual results41
- May 12, 2022Reported quarterly or annual results42
- Mar 23, 2022Reported quarterly or annual results43
- Nov 9, 2021Reported quarterly or annual results44
Upcoming dates from Nasdaq's calendar; past results from the company's 8-K filings (Item 2.02). The full markets calendar
Filings
84 filings to the SEC since October 2021: 3 annual reports, 5 quarterly reports, 28 major events, 21 insider forms, 11 large holders, 16 other. The latest 20:
- Feb 9, 2024SC 13G/A EDGAR
- Dec 21, 20238-K EDGAR
- Dec 18, 20238-K EDGAR
- Jul 3, 20238-K EDGAR
- Jun 27, 2023SC 13D/A EDGAR
- Jun 2, 2023DEF 14A EDGAR
- May 24, 2023S-8 POS EDGAR
- May 24, 2023S-8 POS EDGAR
- May 24, 2023S-8 POS EDGAR
- May 24, 2023S-8 POS EDGAR
- May 24, 2023RW EDGAR
- May 23, 2023PRE 14A EDGAR
- May 18, 202310-Q EDGAR
- May 15, 2023NT 10-Q EDGAR
- May 11, 20238-K EDGAR
- May 5, 20238-K EDGAR
- Apr 28, 202310-K/A EDGAR
- Apr 25, 20238-K EDGAR
- Apr 18, 20238-K EDGAR
- Mar 30, 202310-K EDGAR
The 84 filings since October 2021 can be filtered by form type and year here when JavaScript is on.
Every filing from the last five years, summarized. The full record is on SEC EDGAR.
Insider trades
7 open-market trades by officers, directors and large owners since October 2021: 7 buys and 0 sales. Grants, option exercises and gifts are left out.
| Date | Who | Trade | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| Jan 13, 2022 | Miller Joan W.Director | Buy | 17,700 | $2.83 | $50.1K | Form 4 |
| Dec 6, 2021 | RIEDEL NORBERT GEXECUTIVE CHAIRMAN OF THE BOD | Buy | 100,000 | $2.23 | $223.0K | Form 4 |
| Dec 2, 2021 | KHANNA ASHISHCFO AND CBO | Buy | 45,000 | $2.26 | $101.7K | Form 4 |
| Nov 12, 2021 | HOMBACH ROBERT J.Director | Buy | 74,600 | $2.40 | $179.0K | Form 4 |
| Nov 12, 2021 | HOMBACH ROBERT J.Director | Buy | 74,600 | $2.40 | $179.0K | Form 4 |
| Nov 11, 2021 | HOMBACH ROBERT J.Director | Buy | 5,400 | $2.40 | $13.0K | Form 4 |
| Nov 11, 2021 | HOMBACH ROBERT J.Director | Buy | 5,400 | $2.40 | $13.0K | Form 4 |
From Forms 4 filed with the SEC.
Major holders
Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.
- Artal International S.C.A.SC 13G/A, 2 filings Feb 13, 2023 to Feb 9, 202445
- ADAMS STREET PARTNERS LLCSC 13D/A, 1 filing Jun 27, 202346
- Longitude Capital Partners II, LLCSC 13D/A, 2 filings Feb 14, 2023 to Mar 16, 202347
- John A. KryzanowskiSC 13G/A, 5 filings Jun 24, 2022 to Jan 20, 202348
- New Leaf Ventures III, L.P.SC 13D/A, 1 filing Feb 11, 202249
SEC filer profile
How Aptinyx Inc. is registered with the Securities and Exchange Commission, from its EDGAR record and the cover page of its latest annual report.
- Name on EDGARAptinyx Inc.1
- CIK0001674365
- Employer ID (EIN)47-46260571
- Filer status<br>emerging growth company1
- Incorporated inDelaware1
- Fiscal year endsDecember 311
- Industry code (SIC)2834 Pharmaceutical Preparations1
- SEC reviewing officeOffice of Life Sciences, Division of Corporation Finance1
- Business address1801 Maple Avenue, Suite 4300, Evanston, IL 602011
- Mailing address909 Davis Street, Suite 600, Evanston, IL 602011
- Phone847-871-03771
- Shares outstanding67,715,718 as of May 15, 202310
- Public float$38 as of Jun 30, 202250
- On EDGAR sinceMay 19, 20161
- Filings348 in all: 4 (150), 8-K (66), 3 (22), 10-Q (15), SC 13D/A (12), SC 13G/A (8), 424B5 (7), 10-K (5)1
All 37 form types
CORRESP (5), DEF 14A (5), SC 13D (5), DEFA14A (4), S-8 (4), S-8 POS (4), SC 13G (4), 4/A (3), 8-K/A (3), EFFECT (3), UPLOAD (3), D (2), S-3 (2), 10-K/A (1), 25-NSE (1), 424B4 (1), 8-A12B (1), CERT (1), CT ORDER (1), DEFR14A (1), DRS (1), DRS/A (1), DRSLTR (1), NT 10-Q (1), PRE 14A (1), RW (1), S-1 (1), S-1/A (1), S-1MEF (1)
- Latest filingsAnnual report (10-K) Mar 30, 2023
Quarterly report (10-Q) May 18, 2023
Proxy statement (DEF 14A) Jun 2, 2023
Latest 8-K (8-K) Dec 21, 2023
Sources
The numbers on this page point here. Each one links to the record it came from.
- 1SEC EDGARAptinyx Inc. filings on SEC EDGAR
- 2SEC EDGARAptinyx Inc. filings on SEC EDGAR
- 3SEC EDGARAptinyx Inc. 10-K for fiscal 2021
- 4SEC EDGARAptinyx Inc. 10-K for fiscal 2021
- 5SEC EDGARAptinyx Inc. 10-K for fiscal 2017
- 6SEC EDGARAptinyx Inc. 10-K for fiscal 2018
- 7SEC EDGARAptinyx Inc. 10-K for fiscal 2019
- 8SEC EDGARAptinyx Inc. 10-Q for fiscal 2022
- 9SEC EDGARAptinyx Inc. 10-Q for fiscal 2022
- 10SEC EDGARAptinyx Inc. 10-Q for fiscal 2023
- 11
- 12SEC EDGARNorbert G. Riedel, Chair
- 13
- 14
- 15
- 16
- 17SEC EDGARJoan W. Miller, Board member
- 18SEC EDGARGilmore Neil O'Neill, Board member
- 19SEC EDGARHenry O. Gosebruch, Board member
- 20SEC EDGARRachel E. Sherman, Board member
- 21SEC EDGARAdam Koppel, Board member
- 22SEC EDGARJames N. Topper, Board member
- 23SEC EDGARLiam Ratcliffe, Board member
- 24SEC EDGARPatrick G. Enright, Board member
- 25SEC EDGARRobert J. Hombach, Board member
- 26SEC EDGARTerry P. Gould, Board member
- 27SEC EDGARWilbur H. Gantz, Board member
- 28SEC EDGAROther events
- 29SEC EDGAROther events
- 30
- 31SEC EDGARListing notice or transfer
- 32
- 33SEC EDGAREnded a material agreement
- 34SEC EDGARExecutive or director change
- 35SEC EDGARResults of operations
- 36SEC EDGARExit or restructuring costs
- 37SEC EDGAROther events
- 38SEC EDGARListing notice or transfer
- 39SEC EDGARExecutive or director change
- 40
- 41
- 42
- 43
- 44
- 45
- 46
- 47
- 48
- 49
- 50
- 51SEC EDGARAptinyx Inc. filing with the SEC